These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 14600095)

  • 81. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.
    Workman P
    Mol Cancer Ther; 2003 Feb; 2(2):131-8. PubMed ID: 12589030
    [No Abstract]   [Full Text] [Related]  

  • 82. [Study on signal transduction pathway in differentiation and apoptosis of leukemia cells induced by heat shock protein inhibitor].
    Yu WJ; Rao Q; Wang M; Tian Z; Xu ZF; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):677-80. PubMed ID: 18399173
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.
    Enmon R; Yang WH; Ballangrud AM; Solit DB; Heller G; Rosen N; Scher HI; Sgouros G
    Cancer Res; 2003 Dec; 63(23):8393-9. PubMed ID: 14679001
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Topically applied Hsp90 inhibitor 17AAG inhibits UVR-induced cutaneous squamous cell carcinomas.
    Singh A; Singh A; Sand JM; Bauer SJ; Hafeez BB; Meske L; Verma AK
    J Invest Dermatol; 2015 Apr; 135(4):1098-1107. PubMed ID: 25337691
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
    Terry J; Lubieniecka JM; Kwan W; Liu S; Nielsen TO
    Clin Cancer Res; 2005 Aug; 11(15):5631-8. PubMed ID: 16061882
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Altered molecular pathways decides the treatment outcome of Hsp90 inhibitors against breast cancer cells.
    Vykuntham NG; Suran S; Siripini S; John S; Kumar P; Paithankar K; Amere Subbarao S
    Toxicol In Vitro; 2020 Jun; 65():104828. PubMed ID: 32184171
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
    Moser C; Lang SA; Kainz S; Gaumann A; Fichtner-Feigl S; Koehl GE; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2007 Nov; 6(11):2868-78. PubMed ID: 18025273
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM.
    Calabrese C; Frank A; Maclean K; Gilbertson R
    J Biol Chem; 2003 Jul; 278(27):24951-9. PubMed ID: 12709419
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.
    Johnston JS; Phelps MA; Blum KA; Blum W; Grever MR; Farley KL; Dalton JT
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Aug; 871(1):15-21. PubMed ID: 18635408
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The clinical applications of heat shock protein inhibitors in cancer - present and future.
    Banerji U; Judson I; Workman P
    Curr Cancer Drug Targets; 2003 Oct; 3(5):385-90. PubMed ID: 14529390
    [TBL] [Abstract][Full Text] [Related]  

  • 92. 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.
    Walker T; Mitchell C; Park MA; Yacoub A; Rahmani M; Häussinger D; Reinehr R; Voelkel-Johnson C; Fisher PB; Grant S; Dent P
    Mol Cancer Ther; 2010 May; 9(5):1378-95. PubMed ID: 20442308
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation.
    Guo W; Siegel D; Ross D
    J Pharm Sci; 2008 Dec; 97(12):5147-57. PubMed ID: 18393300
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.
    Arlander SJ; Eapen AK; Vroman BT; McDonald RJ; Toft DO; Karnitz LM
    J Biol Chem; 2003 Dec; 278(52):52572-7. PubMed ID: 14570880
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Differential effects of Hsp90 inhibition on corneal cells in vitro and in vivo.
    Raghunathan V; Edwards SG; Leonard BC; Kim S; Evashenk AT; Song Y; Rewinski E; Marangakis Price A; Hoehn A; Chang C; Reilly CM; Muppala S; Murphy CJ; Thomasy SM
    Exp Eye Res; 2021 Jan; 202():108362. PubMed ID: 33220237
    [TBL] [Abstract][Full Text] [Related]  

  • 96. 17-AAG: mechanisms of antitumour activity.
    Konstantinopoulos PA; Papavassiliou AG
    Expert Opin Investig Drugs; 2005 Dec; 14(12):1471-4. PubMed ID: 16307487
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment.
    Lodi A; Ronen SM
    PLoS One; 2011; 6(10):e26155. PubMed ID: 22022547
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.
    Nielsen TO; Andrews HN; Cheang M; Kucab JE; Hsu FD; Ragaz J; Gilks CB; Makretsov N; Bajdik CD; Brookes C; Neckers LM; Evdokimova V; Huntsman DG; Dunn SE
    Cancer Res; 2004 Jan; 64(1):286-91. PubMed ID: 14729636
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy.
    Sankaranarayanapillai M; Tong WP; Maxwell DS; Pal A; Pang J; Bornmann WG; Gelovani JG; Ronen SM
    Mol Cancer Ther; 2006 May; 5(5):1325-34. PubMed ID: 16731766
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.
    Le HC; Lupu M; Kotedia K; Rosen N; Solit D; Koutcher JA
    Magn Reson Med; 2009 Nov; 62(5):1112-9. PubMed ID: 19780165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.